Surface-modified cobalt oxide nanoparticles: new opportunities for anti-cancer drug development
© Springer-Verlag 2012
Received: 22 December 2011
Accepted: 8 March 2012
Published: 27 May 2012
The development of smart nanoparticles that can exhibit the anti-cancer activity, introduces better efficacy and lower toxicity for treatment. The present study was aimed to evaluate the anti-cancer activity of surface functionalized CoO nanoparticles against Jurkat (T-cell lymphoma) and KB (oral carcinoma) cell lines. The nano-sized cobalt oxide nanoparticles (CoO) was prepared by thermal decomposition method followed by surface modification using phosphonomethyl iminodiacetic acid (PMIDA). The PMIDA-coated CoO nanoparticle was characterized by X-ray diffraction, dynamic light scattering, and transmission electron microscopy; and the conjugation was analyzed by Fourier transform infrared spectroscopy. The resultant nanoparticles with an average size less than 100 nm measured by dynamic light scattering and transmission electron microscopy. Cytotoxicity study, flow cytometric analysis and scanning electron micrographs have been revealed that PMIDA-coated nanoparticles significantly enhances the cellular uptake of the nanoparticle and thus facilitates apoptosis of cancer cell (Jurkat and KB). For the application of PMIDA-coated CoO nanoparticles in the medical field, doxorubicin, a potent anti-cancer drug, has been used in similar fashion in this experimental design and all these effects or patterns were observed.
KeywordsCobalt oxide nanoparticles Cancer cell line Anti-cancer drug Cytotoxicity Cellular apoptosis SEM micrographs
The rapid developments of various modified nanoparticles (NP) are attracting increased attention because of their potential in a wide range of biotechnological applications, especially in advance biomedical application (Liong et al. 2008), drug delivery systems (Cheng et al. 2006), and vaccine administration (Schreiber et al. 2010). One of the most interesting chemical elements used as nanoparticles for biomedical applications is cobalt (Co) which is mainly used as cobalt oxide and has an organo-metal compound or a biopolymer (Wang et al. 2005). In spite of its physiological role as a co-factor of vitamin B12, cobalt cannot be regarded only as an essential element. Cobalt-based NPs, in general, cobalt oxide nanoparticles, in particular, are currently attracting enormous interest owing to their unique size- and shape-dependent properties and potential applications in pigments, catalysis, sensors, electrochemistry, magnetism, energy storage, etc. (Liu et al. 2005).
The uses of polymeric nanoparticles with functional properties have been widely used in a broad range of bio applications; like drug and gene delivery, cell and tissue engineering, diagnostic and therapeutic purposes etc. (Uhrich et al. 1999; Panyam and Labhasetwar 2003; Marin et al. 2005; Marinakos et al. 2001). Among these applications, the field of drug delivery by nanoparticles with specific and rapid internalization into a target cell has immense promise (Maeda et al. 2009; Faraji and Wipf 2009; Singh and Lillard 2009; Breunig et al. 2008; Brannon-Peppas and Blanchester 2004). Nanoparticles of polymer not only protect the bioactive substance but also facilitate the control release of the material in delivering system (Vauthier et al. 2003; Liang et al. 2006; Sheikh et al. 2009; Mitra et al. 2001). Therefore, in the present paper, we have focused our interest on the study of modified CoO NPs. Believing that the characterization of the physical–chemical properties of NP is relevant for the study of their biological activity, we analyzed CoO NP morphology by electron microscopy in order to define aggregation, size, and shape. These properties may have a significant influence on their biological effects. This present study was aimed to develop a novel and economically viable nanoparticles which have anti-cancer activity to cancer cell in vitro.
2 Materials and methods
2.1 Chemicals and reagents
Phosphonomethyl iminodiacetic acid (PMIDA), propidium iodide, cobalt chloride (CoCl2·3H2O), RNaseA, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT reagent), Histopaque 1077, and Rhodamine isothiocyanate (RITC) were procured from Sigma (St. Louis, MO, USA). Minimum essential medium (MEM), RPMI 1640, fetal bovine serum (FBS), penicillin, streptomycin, doxorubicin, sodium chloride (Nacl), sodium carbonate (Na2CO3), sucrose, Hanks balanced salt solution, and ethylene diamine tetra acetate were purchased from Himedia, India. Tris–HCl, Tris buffer, KH2PO4, K2HPO4, Hcl, formaldehyde, alcohol, and other chemicals were procured from Merck Ltd., SRL Pvt. Ltd., Mumbai, India. Commercially available dimethyl sulfoxide was procured from Himedia, India, and was purified by vacuum distillation over KOH. All other chemicals were from Merck Ltd., SRL Pvt., Ltd., Mumbai, and were of the highest purity grade available.
2.2 Synthesis of cobalt oxide nanoparticles
Cobalt oxide NPs were prepared by thermal decomposition method. The starting materials were CoCl2·3H2O, Na2CO3. Two grams of starting material (CoCl2·3H2O) was taken in a beaker and mixed with Na2CO3 as a molar ratio 1:1. Then the solution was rotated 1 h at room temperature. After that the precipitations were collected by centrifugation to obtain the nanoparticle precursor. The precursor was calcinated at 300 °C in air in a porcelain crucible for 2 h to get cobalt oxide NPs.
2.3 Surface modification of synthesized cobalt oxide nanoparticles
Thirty milligrams of synthesized cobalt oxide NPs was dispersed in 10 ml of milli-Q (Millipore) to make a solution 3 mg/ml. Another solution of PMIDA was prepared by dissolving 27 mg PMIDA in 10 ml of distilled water. Then this solution was mixed with above solution. The pH of the medium was maintained at 10 and stirring for 12 h. After that particles were collected by centrifugation. Then the recovered particles were washed three times with milli-Q (Millipore).
2.4 Characterization of synthesized surface modified cobalt nanoparticles
2.4.1 X-ray diffraction study
The phase formation and crystallographic state of cobalt oxide NPs were determined by XRD with an Expert Pro (Phillips) X-ray diffractometer using CoKα radiation (¥ = 0.178 nm). Samples were scanned from 20° to 80° of 2θ increment of 0.04° with 2 s counting time. Hydrodynamic size of the cobalt oxide nanoparticles aggregates was measured in a Brookhaven 90 Plus particle size analyzer (Chakraborty et al. 2010).
2.4.2 Dynamic light scattering
Dynamic light scattering (DLS) analysis was done by Zetasizer Nano ZS (Malvern Instruments) according to the method of Chakraborty et al. (2010) with some modifications. The concentration of the cobalt oxide nanoparticles was 100 μg/ml and was sonicated for 2 min and dynamic particle sizes were measured suspending two drops of aqueous suspension of nanoparticles in 10 ml of Millipore water. When particle was completely dispersed in water then particle was analyzed with a dynamic light scattering analyzer. The experiments were repeated several times to get average size of nanoparticles.
2.4.3 Transmission electron micrography
The particle size and microstructure were studied by high-resolution transmission electron microscopy in a JEOL 3010, Japan operating at 200 kV according to the method of Chakraborty et al. (2010) with some modifications. In brief, cobalt oxide nanoparticles was suspended in deionized at a concentration of 1 mg/ml then the sample was sonicate using a sonicator bath until sample form a homogenous suspension. For size measurement, sonicated stock solution of all cobalt oxide nanoparticles (0.5 mg/ml) was diluted 20 times. TEM was used to characterize the size and shape of the cobalt oxide nanoparticles. A drop of aqueous cobalt oxide nanoparticles suspension was placed on to carbon-coated copper grid and this was dried in air to get TEM image.
2.4.4 Fourier transform infrared spectroscopy
The conjugation of PMIDA with CoO nanoparticles was investigated by the FTIR with a model Thermo Nicolet Nexux-model 870 according to the method of Chakraborty et al. (2010) with some modifications. In brief, 1.0 mg sticky mass of PMIDA-coated CoO nanoparticles with 100 μl KBr medium and a thin film was prepared on the Nacl plate by drop casting method and under atmosphere separately. The FTIR value was taken within 500 to 4,000 wave numbers (cm−1).
2.5 Selection of human subjects for collection of lymphocytes and oral squamous epithelial cell
Six healthy subjects were chosen to collect the blood sample for separation of lymphocytes and collection of squamous epithelial cell by scraping. All subjects enrolled in this study were asymptomatic and none of them had abnormality on physical examinations and routine laboratory tests. All the subjects were from same geographical area and same economic status, non-smokers and non-alcoholic, and having same food habit. These subjects received no medication, including vitamin E and vitamin C. All subjects gave informed consent. The selection excluded not only individuals with acute infections or chronic diseases, but also excluded healthy individuals undergoing supplementation with antioxidative substances. The study protocol was in accordance with the declaration of Helsinki, and was approved by the ethical committee of Vidyasagar University.
2.5.1 Separation of lymphocytes
Fasting blood samples were collected from all groups of individuals satisfying the Helsinki protocol. The lymphocytes were isolated from heparinized blood samples according to the method of Hudson and Hay (Hudson et al. 1991). Blood was taken and diluted with phosphate-buffered saline (pH 7.0) in equal ratio and then layered very carefully on the density gradient (histopaque) in 1:2 ratio, centrifuged at 500×g for 40 min and the white milky layer of mononuclear cells, i.e., lymphocytes were carefully removed. The layer was washed twice with the same buffer and then centrifuged at 2400 rpm for 10 min to get the required pellet of lymphocytes.
2.5.2 Collection of oral squamous epithelial cells
Mucosal scrapings were placed in medium MEM supplemented with 10 % fetal bovine serum and then passed through a sterile 100-mm nylon mesh followed by further washes with MEM complete medium. Filtrate was then centrifuged at 2,200–2,400 rpm for 5 min and the supernatant discarded. The cell pellet is suspended in MEM supplemented with 10 % fetal bovine serum, 100 μg/ml streptomycin, and 100 U/ml penicillin (Steele and Fidel 2002).
2.6 Cell culture
The normal human lymphocytes and oral squamous epithelial cells, T-cell lymphoma (Jurkat) and oral epithelial cancer (KB) cell lines were cultivated for in vitro experiments. Cell lines were obtained from the National Centre for Cell Sciences, Pune, India. It was cultured in RPMI 1640 medium and minimal essential medium supplemented with 10 % fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin, 4 mM l-glutamine under 5 % CO2, and 95 % humidified atmosphere at 37 °C.
2.7 Preparation of drug
Several doses of PMIDA-coated CoO nanoparticles and doxorubicin (1–25 μg/ml) were prepared using sterile phosphate buffer saline (pH 7.4). In this study, all these doses were charged against normal and cancer cell line for evaluation of in vitro anti-cancer activity.
2.8 Experimental design
- Group I
Control, i.e., cells in culture media
- Group II
Cells + 1 μg/ml doxorubicin in culture media
- Group III
Cells + 1 μg/ml PMIDA-coated CoO nanoparticles in culture media
- Group IV
Cells + 5 μg/ml doxorubicin in culture media
- Group V
Cells + 5 μg/ml PMIDA-coated CoO nanoparticles in culture media
- Group VI
Cells + 10 μg/ml doxorubicin in culture media
- Group VII
Cells + 10 μg/ml PMIDA-coated CoO nanoparticles in culture media
- Group VIII
Cells + 25 μg/ml doxorubicin in culture media
- Group IX
Cells + 25 μg/ml PMIDA-coated CoO nanoparticles in culture media
After the treatment schedule, the cells were collected from the Petri dishes separately and centrifuged at 2,200 rpm for 10 min at 4 °C. The cells were washed twice with 50 mM PBS, pH 7.4 and then processed for the biochemical estimation (Sandhu and Kaur 2002).
2.9 In vitro cytotoxicity
Normal human lymphocytes and oral squamous epithelial cell, Jurkat and KB cell lines were seeded into 96 wells of tissue culture plates having 180 μl of complete media and were incubated for 48 h. Doxorubicin and PMIDA-coated CoO nanoparticles were added to the cells at different concentrations (1, 5, 10, and 25 μg/ml), were incubated for 48 h at 37 °C in a humidified incubator (NBS) maintained with 5 % CO2. The cell viability was estimated by 3-(4,5-dimethylthiazol)-2-diphenyltetrazolium bromide according to the method of our previous laboratory report Chakraborty et al. 2011.
2.10 Detection of cellular apoptosis by flow cytometric analysis using propidium iodide
Cell apoptosis was measured using propidium iodide staining and analysis by flow cytometry (Roa et al. 2009). After the treatment schedule; the cells were scraped and centrifuged with the supernatant medium at 3,500 rpm for 5 min. Following washes, cells were resuspended in PBS and fixed in 70 % ethanol for 1 h on ice. Fixed cells were washed with PBS and stained with propidium iodide (5 μg/mL) solution containing ribonuclease (RNase; 50 μmol/L) for 30 min at room temperature. Then, cells were analyzed on a Becton Dickinson FACS Calibur flow cytometer. The sub-G0 population of the cells was determined by CellQuest software.
2.11 Alteration of cellular morphology by scanning electron microscope
After the treatment schedule, Jurkat and KB cells were examined under electron microscope according to the method of Papis et al. (2009) to visualize whether the cell undergoes for morphological alteration or not. In brief, treated cells were harvested, fixed in 2 % glutaraldehyde in 0.1 M Na-cacodylate buffer (pH 7.2) for 1 h at room temperature, washed in the same buffer, and post fixed for 1 h with 1 % osmium tetroxide in 0.1 M Na-cacodylate buffer (pH 7.2) at room temperature and dehydrated in graded ethanol and observed under electron microscope.
2.12 Intracellular uptake
Nanoparticle uptake by Jurkat and KB cells was studied by fluorescence microscopy methods according to our previous laboratory report (Sahu et al. 2010). After the treatment schedule, 2 × 105 cells were seeded into 35 mm cell culture plates. It was incubated in a humidified incubator maintained with 5 % CO2 and 37 °C. After 8 h the cells were washed with incomplete media and were incubated with 25 μg/ml DOX/DOX-RITC and PMIDA-coated CoO NP/PMIDA-coated CoO NP-RITC for fluorescence microscopy. Then the cells were allowed to adhere to a glass cover slip in 35-mm Petriplates, followed by incubation for 4 h at 37 °C in a humidified incubator maintained with 5 % CO2. Fluorescence images were acquired with 488 nm laser for differential interference contrast microscopy and 543 nm lasers for RITC excitation on an Olympus research phase contrast with fluorescence microscope (model: CX41; Olympus Singapore Pvt. Ltd., Valley Point Office Tower, Singapore).
2.13 Statistical analysis
The data were expressed as mean±SEM, n = 6. Comparisons between the means of control and treated group were made by one-way ANOVA test (using a statistical package, Origin 6.1, Northampton, MA 01060 USA) with multiple comparison t tests, p < 0.05 as a limit of significance.
3 Result and discussion
3.1 Synthesis of PMIDA-coated CoO nanoparticles
Several data are available about the toxicology of cobalt ions, it is generally accepted that the biological activity and potential toxicity of metallic NPs cannot simply be derived from previous data on ionic forms, indicating the importance of testing the effects of chemicals in nanostructural form (Roco 2005). The nano-sized cobalt oxide nanoparticles (CoO) was prepared by thermal decomposition method followed by surface modification using phosphonomethyl iminodiacetic acid. The phosphonate group of the N phosphonomethyl iminodiacetic acid ligand acts as a surface anchoring agent on nanoparticles and the –COOH remains free at outside.
3.2 Characterization of synthesized surface modified cobalt nanoparticle
3.2.1 X-ray diffraction analysis
3.2.2 Dynamic light scattering experiment
3.2.3 Transmission electron microscopy
3.2.4 Fourier transform infrared spectroscopy
3.3 In vitro toxicity studies
3.4 Cellular apoptosis analysis by flow cytometry using propidium iodide
3.5 Intracellular uptake by scanning electron microscopy and fluorescence imaging
In this study, a simple process has been developed to synthesize PMIDA-coated CoO nanoparticles. This nano polymeric system impact excellent stability in aqueous medium with reasonable good hydrodynamic size. In vitro cytotoxicity test using an MTT assay method showed that this PMIDA-coated CoO nanoparticles has anti-cancer activity; rather than they have no adverse effect on normal cells. Flow cytometry has revealed that nanoparticles are targeting more effectively the cancerous cells. Due to high specific uptake, this system may further be explored for the application of new anti-cancer drug development therapy. The data presented here suggests that further in vivo studies are needed to define the therapeutic index of the tumor-targeting polymeric carrier and will constitute the basis for the next generation drug development. In vivo testing of anti-cancer activity of these nanoparticles is in progress.
The authors express gratefulness to the Department of Biotechnology, Government of India, for funding. The authors also express gratefulness to the Indian Institute of Technology, Kharagpur and Vidyasagar University, Midnapore, for providing the facilities to execute these studies.
Declaration of interest
Authors declare that there are no conflicts of interests.
- Brannon-Peppas L, Blanchester JO (2004) Nanoparticles and targeted system for cancer therapy. Adv Drug Deliv Rev 56:1649–1659. doi:10.1016/j.addr.2004.02.014View ArticleGoogle Scholar
- Breunig M, Bauer S, Goepferich A (2008) Polymers and nanoparticles:intelligent tools for intracellular targeting. Eur J Pharm Biopharm 68:112–128. doi:10.1016/j.ejpb.2007.06.010View ArticleGoogle Scholar
- Chakraborty SP, Sahu SK, Kar Mahapatra S, Santra S, Bal M, Roy S, Pramanik P (2010) Nanoconjugate vancomycin: new oppprtunities for the development of anti-VRSA agents. Nanotechnology 21:105103. doi:10.1088/0957-4484/21/10/105103View ArticleGoogle Scholar
- Chakraborty SP, Sahu SK, Pramanik P, Roy S (2011) Biocompatibility of folate-modified chitosan nanoparticles. Asian Pacific J of Tropical Biomedicine 2(3):215–219View ArticleGoogle Scholar
- Cheng J, Teply BA, Jeong SY, Yim CH, Ho D, Sherifi I, Jon S, Farokhzad OC, Khademhosseini A, Langer RS (2006) Magnetically responsive poltmeric microparticles for oral delivery of protein drugs. Pharm Res 23:557–564. doi:10.1007/s11095-005-9444-5View ArticleGoogle Scholar
- Dhawan A, Kayani MA, Parry JM, Parry E, Anderson D (2003) Aneugenic and clastogenic effects of doxorubicin in human lymphocytes. Mutagenesis 18(6):487–490. doi:10.1093/mutage/geg024View ArticleGoogle Scholar
- Faraji AH, Wipf P (2009) Nanoparticles in cellular drug delivery. Bio-org Med Chem 17:2950–2962. doi:10.1016/j.bmc.2009.02.043View ArticleGoogle Scholar
- Gojova A, Guo B, Kota RS, Rutledge JC, Kennedy IM, Barakat AI (2007) Induction of inflammation in vascular endothelial cells by metal oxide nanoparticles: effects of particle composition. Environ Health Persp 155:403–409. doi:10.1289/ehp.8497Google Scholar
- Hudson L, Hay FC (1991) Practical immunology, 3rd Ed. Blackwell Scientific Publications, Oxford. 21–22Google Scholar
- Karim S, Bhandari U, Kumar H, Salam A, Siddiqui M, Pillai KK (2001) Doxorubicin-induced cardiotoxicity and its modulation by drugs. Ind J Pharmaco 3:203–207Google Scholar
- Liang HF, Chen CT, Chen SC, Kulkarni AR, Chiu YL, Chen MC et al (2006) Paclitaxel-loaded poly(g-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials 27:2051–2059. doi:10.1021/bc0502107View ArticleGoogle Scholar
- Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI (2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2:889–896. doi:10.1021/nn800072tView ArticleGoogle Scholar
- Liu X, Qiu G, Li X (2005) Shape-controlled synthesis and properties of uniform spinel cobalt oxide nanotubes. Nanotechnology 16:3035–3040. doi:10.1088/0957-4484/16/12/051View ArticleGoogle Scholar
- Maeda H, Bharate GY, Daruwalla J (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71:409–419. doi:10.1016/j.ejpb.2008.11.010View ArticleGoogle Scholar
- Marin RV, Ng CH, Wilke M, Tiersch B, Fratzl P, Peter MG (2005) Size controlled hydroxyapatite nanoparticles as self-organized organic–inorganic composite materials. Biomaterials 26:5414–5426. doi:10.1016/j.biomaterials.2005.01.051View ArticleGoogle Scholar
- Marinakos SM, Anderson MF, Ryan JA, Martin LD, Feldheim DL (2001) Encapsulation, permiablity, and cellular uptake characteristics of hollow nanometer-sized conductive polymer capsules. J Phys Chem B 105:8872–8876. doi:10.1021/jp010820dView ArticleGoogle Scholar
- Mitra S, Gaur U, Ghosh PC, Maitra AN (2001) Tumour targeted delivery of encapsulated dextran–doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 74:317–323. doi:10.1016/S0168-3659(01)00342-XView ArticleGoogle Scholar
- Mohapatra S, Mallick SK, Maiti TK, Ghosh SK, Pramanik P (2007) Synthesis of highly stable folic acid conjugated magnetite nanoparticles for targeting cancer cells. Nanotechnology 18:385102–385111. doi:10.1088/0957-4484/18/38/385102View ArticleGoogle Scholar
- Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329–347. doi:10.1016/S0169-409X(02)00228-4View ArticleGoogle Scholar
- Papis E, Rossi F, Raspanti M, Isabella DD, Colombo G, Milzani A, Bernardini G, Gornati R (2009) Engineered cobalt oxide nanoparticles readily enter cells. Toxicol Lett 189:253–259. doi:10.1016/j.toxlet.2009.06.851View ArticleGoogle Scholar
- Peters K, Unger RE, Gatti AM, Sabbioni E, Tsaryk R, Kirkpatrick C (2007) Metallic nanoparticles exhibit paradoxical effects on oxidative stress and proinflammatory response in endothelial cells in vitro. Int J Immunopathol Pharmacol 20:685–695Google Scholar
- Powder diffraction file, card 38-1420 JCPDS-ICDD International Center for Diffraction Data (1991) Swarthmore, PAGoogle Scholar
- Roa W, Xiaojing Z, Guo L, Shaw A, Hu X, Xiong Y, Gulavita S, Patel S, Sun X, Chen J, Moor R, Xing JZ (2009) Gold nanoparticles sensitize radiotherapy of prostate cancer cell by regulation of the cell cycle. Nanotechnology 20:1–9. doi:10.1088/0957-4484/20/37/375101View ArticleGoogle Scholar
- Roco MC (2005) Environmentally responsible development of nanotechnology. Environ Sci Technol 39(5):94A–95AView ArticleGoogle Scholar
- Sahu SK, Mallick SK, Santra S, Maiti TK, Ghosh SK, Pramanik P (2010) In vitro evaluation of folic acid modified carboxymethyl chitosan nanoparticles loaded with doxorubicin for targeted delivery. J Mater Sci: Mater Med 21:1587–1597. doi:10.1007/s10856-010-3998-4Google Scholar
- Sandhu SK, Kaur G (2002) Alterations in oxidative stress scavenger system in aging rat brain and lymphocytes. Biogerontology 3:161–173. doi:10.1023/A:1015643107449View ArticleGoogle Scholar
- Schreiber HA, Prechl J, Jiang H, Zozulya A, Fabry Z, Denes F, Sandor M (2010) Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cells. J Immunol Methods 356:47–59. doi:10.1016/j.jim.2010.02.009View ArticleGoogle Scholar
- Sheikh FA, Barakat NAM, Kanjwal MA, Aryal S, Khil MS, Kim HY (2009) Novel self-assembled amphiphilic poly (epsilon-caprolactone)-grafted-poly (vinyl alcohol) nanoparticles: hydrophobic andhydrophilic drugs carrier nanoparticles. J Mater Sci: Mater Med 20:821–831. doi:10.1007/s10856-008-3637-5Google Scholar
- Singh R, Lillard JW Jr (2009) Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86:215–223. doi:10.1016/j.yexmp.2008.12.004View ArticleGoogle Scholar
- Steele C, Fidel PL Jr (2002) Cytokine and chemokine production by human oral and vaginal epithelial cells in response to Candida albicans. Infection and Immunity 2:577–583. doi:10.1128/IAI.70.2.577-583.2002View ArticleGoogle Scholar
- Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM (1999) Polymeric system for controlled drug release. Chem Rev 99:3181–3198. doi:10.1021/cr940351uView ArticleGoogle Scholar
- Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P (2003) Drug delivery to resistant tumors: the potential of poly (alkylcyanoacrylate) nanoparticles. J Control Release 93:151–160. doi:10.1016/j.jconrel.2003.08.005View ArticleGoogle Scholar
- Wang K, Xu JJ, Chen HY (2005) A novel glucose biosensor based on the nanoscaled cobalt phthalocyanine-glucose oxidase biocomposite. Biosens Bioelectron 20:1388–1396. doi:10.1016/j.bios.2004.06.006View ArticleGoogle Scholar